TIDE and TMB analyses also showed that rare EGFR variants was more likely to respond to PD-L1/PD-1 inhibitors than wild-type, L858R-mutated, and exon 19 deletion-mutated EGFR lung cancers. This evidence concerns the gene PDCD1 and lung carcinoma.